USE OF ERIBULIN AND LENVATINIB AS COMBINATION THERAPY FOR TREATMENT OF CANCER Russian patent published in 2018 - IPC A61K31/357 A61K31/47 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to methods and compositions for use in the treatment of diseases associated with excessive cellular proliferation, such as cancer. Said method of treating a subject having cancer or a risk of cancer and a method for reducing size of a malignant tumor in a subject include administering to the subject eribulin or a pharmaceutically acceptable salt thereof in an amount of 0.1 mg/m² up to 20 mg/m² and lenvatinib or a pharmaceutically acceptable salt thereof in an amount of 0.1 mg to about 100 mg. Also, disclosed is a pharmaceutical composition comprising said ingredients.

EFFECT: group of inventions provides a combined cancer treatment that demonstrates stronger antitumor activity.

35 cl, 3 dwg, 1 tbl, 3 ex